Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in most, if not all tumor types. Until recently, MYC has ...

Findings from a preclinical study demonstrate that Omomyc—the only direct MYC inhibitor to have successfully completed a phase I clinical trial—causes DNA damage in cancer cells which is ...

Cambridge, MA, May 28 — Insilico Medicine (“Insilico”), in collaboration with research partner at Huadong Medicine Company, today announced the discovery of novel small-molecule inhibitors that ...

Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most ...

Combination of a MYC-targeting epigenomic controller with immune checkpoint or EGFR inhibitor enhanced anti-tumor activity in models of NSCLC CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Omega ...

Unless otherwise listed, all solvents and reagents were purchased from Aldrich Chemical Co. (MO, USA) and used as received. Anhydrous chloroform and methanol were purchased from Aldrich Chemical Co.

Researchers at CSH Laboratory identified an oncogenic SRSF1–AURKA–MYC circuit driving pancreatic ductal adenocarcinoma.

Researchers have developed a peptide that targets a previously ‘undruggable’ protein implicated in more than 75% of human cancers and found that it slowed the proliferation of brain cancer cells in ...

This article analyzes the mechanism of c-Myc that induces CDK4/6 inhibitors resistance and introduces A80.2HCl, a promising molecular glue compound developed by Kintor Pharma, to enhance the ...

Researchers at Baylor College of Medicine have identified a small molecule named 5D4 that can suppress the growth of breast and ovarian cancers in animal models. 5D4 works by binding to TopBP1 protein ...